Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML)

Francis Joseph Giles

Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML)

Francis Joseph Giles

Medicine

Research output: Other contribution (Published) › Other contribution

Original language	English (Ireland)
Media of output	Meeting
Volume	118
Publication status	Published - 1 Nov 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@misc{6ac9fee193fc4f6993af8636b86d3f74,

title = "Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML)",

author = "Giles, \{Francis Joseph\}",

year = "2011",

month = nov,

day = "1",

language = "English (Ireland)",

volume = "118",

type = "Other",

}